Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4485807

CCC(=O)O.O=C(O)C(F)(F)F

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 2/20 0.62
CYP2D6 P10635 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
HIF1A Q16665 1/20 0.39
FAAH O00519 8/20 0.39
ACLY P53396 2/20 0.39
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
CES1 P23141 5/20 0.37
CES2 O00748 2/20 0.37
MEN1 O00255 2/20 0.37
CYP1A2 P05177 2/20 0.37
KMT2A Q03164 2/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 2/20 0.37
ALDH1A1 P00352 2/20 0.37
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL20527475 1.00 FFAR3 (0.62) FFAR3CYP2D6TSHRCYP2C19HIF1A
Succinic Acid SCHEMBL27603519 0.87 FFAR3 (0.48) FFAR3TSHRFAAHHDAC3HDAC1
Trifluoroacetic Acid SCHEMBL9785203 0.87 FFAR3 (0.62) FFAR3TSHRFAAHHDAC3HDAC1
Trifluoroacetic Acid SCHEMBL31031817 0.87 FAAH (0.42) FFAR3CYP2D6TSHRCYP2C19HIF1A
Trifluoroacetic Acid SCHEMBL27841664 0.87 FAAH (0.42) FFAR3CYP2D6TSHRCYP2C19HIF1A
Trifluoroacetic Acid SCHEMBL29603858 0.85 ALDH1A1 (0.59) FFAR3FAAHCES1CES2MEN1
Trifluoroacetic Acid SCHEMBL27943966 0.85 FFAR3 (0.42) FFAR3TSHRFAAHCES1CES2
Trifluoroacetic Acid SCHEMBL27632684 0.85 TDP1 (0.59) FFAR3TSHRFAAHCES1CES2
Trifluoroacetic Acid SCHEMBL3794549 0.84 FAAH (0.40) FFAR3CYP2D6TSHRCYP2C19HIF1A
Trifluoroacetic Acid SCHEMBL30324569 0.84 FAAH (0.40) FFAR3CYP2D6TSHRCYP2C19HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104387372-B Oxo azetidine derivatives, preparation method and its purposes in human medical and cosmetics 盖尔德马研究及发展公司 2018-06-26 CN claimed
CN-106795122-A Nitric oxide donor carnosine compounds 尼科斯科学爱尔兰公司 2017-05-31 CN claimed
US-7605267-B2 Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones NOVARTIS AG (CH) 2009-10-20 US claimed
CN-1054842-C Platelet aggregation inhibitors SEARLE & CO (US) 2000-07-26 CN claimed
CN-1218460-A Substituted 4-hydroxy-phenylalcanoic acid derivatives with activity to ppar-'gamma' GLAXO GROUP LTD (GB) 1999-06-02 CN claimed
CN-1124957-A 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors SEARLE & CO (US) 1996-06-19 CN claimed
WO-2026087635-A1 DIHYDRO BENZOXAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 WO disclosed
CN-113226375-B Methods and compositions 英国研究与创新署 2025-05-13 CN disclosed
CN-119677757-A Small molecules for boron neutron capture therapy 艾维克放射性药物有限责任公司 2025-03-21 CN disclosed
US-20250090699-A1 FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2025-03-20 US disclosed
CN-119019309-A GPR40 agonism-SSTR 5 antagonistic double-effect compound, preparation method and application thereof 南昌大学 2024-11-26 CN disclosed
EP-4377318-A1 PYRROLO [2, 3-B] PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND THE USE THEREOF BeiGene, Ltd. (KY) 2024-06-05 EP disclosed
CN-118043324-A Pyrrolo [2,3-b ] pyrazine-based bifunctional compounds as HPK1 degradants and uses thereof 百济神州有限公司 2024-05-14 CN disclosed
WO-1993024475-A1 SULPHAMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS CELLTECH LIMITED (GB) 1993-12-09 WO disclosed
WO-1993014096-A1 PHOSPHONO DERIVATIVES OF AMINO ACIDS AS METALLOPROTEINASE INHIBITORS CELLTECH LIMITED (GB) 1993-07-22 WO disclosed
CN-1063110-A The amides derivative of the antibiotic GE2270 factor GRUPPOLEPETIT S P A (IT) 1992-07-29 CN disclosed
WO-1992009564-A1 PEPTIDYL DERIVATIVES CELLTECH LIMITED (GB) 1992-06-11 WO disclosed
WO-1992009565-A1 PEPTIDYL DERIVATIVES CELLTECH LIMITED (GB) 1992-06-11 WO disclosed
EP-0489577-A1 Peptidyl derivatives CELLTECH LIMITED (GB) 1992-06-10 EP disclosed
EP-0489579-A1 Peptidyl derivatives CELLTECH THERAPEUTICS LIMITED (GB) 1992-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250090699-A1 FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF FAP, FIBP, FGF23 FFAR3 481/4885CYP2D6 4713/4885TSHR 1413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.